# US 5,858,369 A · Anti-acids secretory recombinant BCG vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,369 A
- Document ID: US5858369A
- Status: Granted
- Kind: A
- Application number: 08/975,699
- Filed: 1997-11-21
- Granted: 1999-01-12
- Earliest claimed: 1994-07-29
- Assignees: Ajinomoto Co., Inc.; Japan as represented by Director General of Agency of National Institute of Health
- Inventors: Kazuhiro Matsuo; Yoshitomo Chujo; Akihiro Yamazaki; Mitsuo Honda; Shudo Yamazaki; Hiromichi Tasaka
- Web page: https://patentgrep.com/patent/US5858369A

## CPC

- C07K 14/005: from viruses
- A61P 31/18: for HIV
- C07K 14/35: from Mycobacteriaceae (F)
- C07K 14/473: {alpha-Glycoproteins}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine containing Mycobacterium bovis BCG which secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of a secretory protein, a carrier, having a signal peptide. BCG constituting the present invention secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of an .alpha.-antigen derived from mycobacteria. Said fusion protein has significantly increased antigenicity and immunogenicity. Therefore, when it is inoculated into animals, it is efficiently recognized by B cells which recognize said antigen, thereby effectively inducing the production of an antibody to said antigen. When said BCG itself is inoculated into animals, it continuously secretes said fusion protein in the bodies of the animals while continuously propagating therein. Therefore, said BCG is an extremely useful vaccine.

## Claims

### Claim 1

An immunogenic composition comprising Mycobacterium bovis BCG which secretes a fusion protein,
wherein the fusion protein is an .alpha.-antigen of mycobacteria into which a foreign antigenic peptide has been inserted between adjacent amino acids in a region between position 184 to 203 of the amino acid sequence of the .alpha.-antigen.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the foreign antigenic peptide is inserted between residues 184 and 185 of the amino acid sequence of the .alpha.-antigen.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, wherein residue 184 is Ser and residue 185 is Asp.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the .alpha.-antigen is the .alpha.-antigen of Mycobacterium kansasii.

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, wherein the foreign antigenic peptide has a length of at most 19 amino acid residues.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein the foreign antigenic peptide is inserted into the molecular surface of the .alpha.-antigen.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein the foreign antigenic peptide is an antigenic peptide of an HIV-1 surface antigen.

### Claim 8 (depends on 7)

The immunogenic composition of claim 7, wherein the foreign antigenic peptide comprises the third variable region of HIV-1.

### Claim 9 (depends on 8)

The immunogenic composition of claim 8, wherein the foreign antigenic peptide has the amino acid sequence of SEQ ID NO: 1.

### Claim 10 (depends on 8)

The immunogenic composition of claim 8, wherein the foreign antigenic peptide has the amino acid sequence of SEQ ID NO: 14, 15, 16, 17 or 18.

### Claim 11 (depends on 8)

The immunogenic composition of claim 8, wherein the foreign antigenic peptide has the amino acid sequence of SEQ ID NO: 13.

### Claim 12 (depends on 1)

A method of inducing an immune response, comprising administering an amount of the immunogenic composition of claim 1 to a patient effective for inducing an immune response.

### Claim 13 (depends on 7)

A method of inducing an immune response, comprising administering an amount of the immunogenic composition of claim 7 to a patient effective for inducing an immune response.

### Claim 14 (depends on 1)

A method of inducing antibody production, comprising administering an amount of the immunogenic composition of claim 1 to a patient effective for inducing antibody production.

### Claim 15 (depends on 1)

A method of inducing cytotoxic T lymphocytes, comprising administering an amount of the immunogenic composition of claim 1 to a patient effective for inducing cytotoxic T lymphocytes.

### Claim 16 (depends on 1)

A method of producing the immunogenic composition of claim 1, comprising transforming Mycobacterium bovis BCG with a DNA sequence encoding a fusion protein,
wherein the fusion protein is an .alpha.-antigen of a mycobacteria into which a foreign antigenic peptide has been inserted between adjacent amino acids in a region between position 184 to 203 of the amino acid sequence of the .alpha.-antigen.
